Kern-basierte Lernverfahren für das virtuelle Screening

We investigate the utility of modern kernel-based machine learning methods for ligand-based virtual screening. In particular, we introduce a new graph kernel based on iterative graph similarity and optimal assignments, apply kernel principle component analysis to projection error-based novelty detection, and discover a new selective agonist of the peroxisome proliferator-activated receptor gamma using Gaussian process regression. Virtual screening, the computational ranking of compounds with respect to a predicted property, is a cheminformatics problem relevant to the hit generation phase of drug development. Its ligand-based variant relies on the similarity principle, which states that (structurally) similar compounds tend to have similar properties. We describe the kernel-based machine learning approach to ligand-based virtual screening; in this, we stress the role of molecular representations, including the (dis)similarity measures defined on them, investigate effects in high-dimensional chemical descriptor spaces and their consequences for similarity-based approaches, review literature recommendations on retrospective virtual screening, and present an example workflow. Graph kernels are formal similarity measures that are defined directly on graphs, such as the annotated molecular structure graph, and correspond to inner products. We review graph kernels, in particular those based on random walks, subgraphs, and optimal vertex assignments. Combining the latter with an iterative graph similarity scheme, we develop the iterative similarity optimal assignment graph kernel, give an iterative algorithm for its computation, prove convergence of the algorithm and the uniqueness of the solution, and provide an upper bound on the number of iterations necessary to achieve a desired precision. In a retrospective virtual screening study, our kernel consistently improved performance over chemical descriptors as well as other optimal assignment graph kernels. Chemical data sets often lie on manifolds of lower dimensionality than the embedding chemical descriptor space. Dimensionality reduction methods try to identify these manifolds, effectively providing descriptive models of the data. For spectral methods based on kernel principle component analysis, the projection error is a quantitative measure of how well new samples are described by such models. This can be used for the identification of compounds structurally dissimilar to the training samples, leading to projection error-based novelty detection for virtual screening using only positive samples. We provide proof of principle by using principle component analysis to learn the concept of fatty acids. The peroxisome proliferator-activated receptor (PPAR) is a nuclear transcription factor that regulates lipid and glucose metabolism, playing a crucial role in the development of type 2 diabetes and dyslipidemia. We establish a Gaussian process regression model for PPAR gamma agonists using a combination of chemical descriptors and the iterative similarity optimal assignment kernel via multiple kernel learning. Screening of a vendor library and subsequent testing of 15 selected compounds in a cell-based transactivation assay resulted in 4 active compounds. One compound, a natural product with cyclobutane scaffold, is a full selective PPAR gamma agonist (EC50 = 10 +/- 0.2 muM, inactive on PPAR alpha and PPAR beta/delta at 10 muM). The study delivered a novel PPAR gamma agonist, de-orphanized a natural bioactive product, and, hints at the natural product origins of pharmacophore patterns in synthetic ligands.Wir untersuchen moderne Kern-basierte maschinelle Lernverfahren für das Liganden-basierte virtuelle Screening. Insbesondere entwickeln wir einen neuen Graphkern auf Basis iterativer Graphähnlichkeit und optimaler Knotenzuordnungen, setzen die Kernhauptkomponentenanalyse für Projektionsfehler-basiertes Novelty Detection ein, und beschreiben die Entdeckung eines neuen selektiven Agonisten des Peroxisom-Proliferator-aktivierten Rezeptors gamma mit Hilfe von Gauß-Prozess-Regression. Virtuelles Screening ist die rechnergestützte Priorisierung von Molekülen bezüglich einer vorhergesagten Eigenschaft. Es handelt sich um ein Problem der Chemieinformatik, das in der Trefferfindungsphase der Medikamentenentwicklung auftritt. Seine Liganden-basierte Variante beruht auf dem Ähnlichkeitsprinzip, nach dem (strukturell) ähnliche Moleküle tendenziell ähnliche Eigenschaften haben. In unserer Beschreibung des Lösungsansatzes mit Kern-basierten Lernverfahren betonen wir die Bedeutung molekularer Repräsentationen, einschließlich der auf ihnen definierten (Un)ähnlichkeitsmaße. Wir untersuchen Effekte in hochdimensionalen chemischen Deskriptorräumen, ihre Auswirkungen auf Ähnlichkeits-basierte Verfahren und geben einen Literaturüberblick zu Empfehlungen zur retrospektiven Validierung, einschließlich eines Beispiel-Workflows. Graphkerne sind formale Ähnlichkeitsmaße, die inneren Produkten entsprechen und direkt auf Graphen, z.B. annotierten molekularen Strukturgraphen, definiert werden. Wir geben einen Literaturüberblick über Graphkerne, insbesondere solche, die auf zufälligen Irrfahrten, Subgraphen und optimalen Knotenzuordnungen beruhen. Indem wir letztere mit einem Ansatz zur iterativen Graphähnlichkeit kombinieren, entwickeln wir den iterative similarity optimal assignment Graphkern. Wir beschreiben einen iterativen Algorithmus, zeigen dessen Konvergenz sowie die Eindeutigkeit der Lösung, und geben eine obere Schranke für die Anzahl der benötigten Iterationen an. In einer retrospektiven Studie zeigte unser Graphkern konsistent bessere Ergebnisse als chemische Deskriptoren und andere, auf optimalen Knotenzuordnungen basierende Graphkerne. Chemische Datensätze liegen oft auf Mannigfaltigkeiten niedrigerer Dimensionalität als der umgebende chemische Deskriptorraum. Dimensionsreduktionsmethoden erlauben die Identifikation dieser Mannigfaltigkeiten und stellen dadurch deskriptive Modelle der Daten zur Verfügung. Für spektrale Methoden auf Basis der Kern-Hauptkomponentenanalyse ist der Projektionsfehler ein quantitatives Maß dafür, wie gut neue Daten von solchen Modellen beschrieben werden. Dies kann zur Identifikation von Molekülen verwendet werden, die strukturell unähnlich zu den Trainingsdaten sind, und erlaubt so Projektionsfehler-basiertes Novelty Detection für virtuelles Screening mit ausschließlich positiven Beispielen. Wir führen eine Machbarkeitsstudie zur Lernbarkeit des Konzepts von Fettsäuren durch die Hauptkomponentenanalyse durch. Der Peroxisom-Proliferator-aktivierte Rezeptor (PPAR) ist ein im Zellkern vorkommender Rezeptor, der den Fett- und Zuckerstoffwechsel reguliert. Er spielt eine wichtige Rolle in der Entwicklung von Krankheiten wie Typ-2-Diabetes und Dyslipidämie. Wir etablieren ein Gauß-Prozess-Regressionsmodell für PPAR gamma-Agonisten mit chemischen Deskriptoren und unserem Graphkern durch gleichzeitiges Lernen mehrerer Kerne. Das Screening einer kommerziellen Substanzbibliothek und die anschließende Testung 15 ausgewählter Substanzen in einem Zell-basierten Transaktivierungsassay ergab vier aktive Substanzen. Eine davon, ein Naturstoff mit Cyclobutan-Grundgerüst, ist ein voller selektiver PPAR gamma-Agonist (EC50 = 10 +/- 0,2 muM, inaktiv auf PPAR alpha und PPAR beta/delta bei 10 muM). Unsere Studie liefert einen neuen PPAR gamma-Agonisten, legt den Wirkmechanismus eines bioaktiven Naturstoffs offen, und erlaubt Rückschlüsse auf die Naturstoffursprünge von Pharmakophormustern in synthetischen Liganden

Computational approaches to virtual screening in human central nervous system therapeutic targets

In the past several years of drug design, advanced high-throughput synthetic and analytical chemical technologies are continuously producing a large number of compounds. These large collections of chemical structures have resulted in many public and commercial molecular databases. Thus, the availability of larger data sets provided the opportunity for developing new knowledge mining or virtual screening (VS) methods. Therefore, this research work is motivated by the fact that one of the main interests in the modern drug discovery process is the development of new methods to predict compounds with large therapeutic profiles (multi-targeting activity), which is essential for the discovery of novel drug candidates against complex multifactorial diseases like central nervous system (CNS) disorders. This work aims to advance VS approaches by providing a deeper understanding of the relationship between chemical structure and pharmacological properties and design new fast and robust tools for drug designing against different targets/pathways. To accomplish the defined goals, the first challenge is dealing with big data set of diverse molecular structures to derive a correlation between structures and activity. However, an extendable and a customizable fully automated in-silico Quantitative-Structure Activity Relationship (QSAR) modeling framework was developed in the first phase of this work. QSAR models are computationally fast and powerful tool to screen huge databases of compounds to determine the biological properties of chemical molecules based on their chemical structure. The generated framework reliably implemented a full QSAR modeling pipeline from data preparation to model building and validation. The main distinctive features of the designed framework include a)efficient data curation b) prior estimation of data modelability and, c)an-optimized variable selection methodology that was able to identify the most biologically relevant features responsible for compound activity. Since the underlying principle in QSAR modeling is the assumption that the structures of molecules are mainly responsible for their pharmacological activity, the accuracy of different structural representation approaches to decode molecular structural information largely influence model predictability. However, to find the best approach in QSAR modeling, a comparative analysis of two main categories of molecular representations that included descriptor-based (vector space) and distance-based (metric space) methods was carried out. Results obtained from five QSAR data sets showed that distance-based method was superior to capture the more relevant structural elements for the accurate characterization of molecular properties in highly diverse data sets (remote chemical space regions). This finding further assisted to the development of a novel tool for molecular space visualization to increase the understanding of structure-activity relationships (SAR) in drug discovery projects by exploring the diversity of large heterogeneous chemical data. In the proposed visual approach, four nonlinear DR methods were tested to represent molecules lower dimensionality (2D projected space) on which a non-parametric 2D kernel density estimation (KDE) was applied to map the most likely activity regions (activity surfaces). The analysis of the produced probabilistic surface of molecular activities (PSMAs) from the four datasets showed that these maps have both descriptive and predictive power, thus can be used as a spatial classification model, a tool to perform VS using only structural similarity of molecules. The above QSAR modeling approach was complemented with molecular docking, an approach that predicts the best mode of drug-target interaction. Both approaches were integrated to develop a rational and re-usable polypharmacology-based VS pipeline with improved hits identification rate. For the validation of the developed pipeline, a dual-targeting drug designing model against Parkinson’s disease (PD) was derived to identify novel inhibitors for improving the motor functions of PD patients by enhancing the bioavailability of dopamine and avoiding neurotoxicity. The proposed approach can easily be extended to more complex multi-targeting disease models containing several targets and anti/offtargets to achieve increased efficacy and reduced toxicity in multifactorial diseases like CNS disorders and cancer. This thesis addresses several issues of cheminformatics methods (e.g., molecular structures representation, machine learning, and molecular similarity analysis) to improve and design new computational approaches used in chemical data mining. Moreover, an integrative drug-designing pipeline is designed to improve polypharmacology-based VS approach. This presented methodology can identify the most promising multi-targeting candidates for experimental validation of drug-targets network at the systems biology level in the drug discovery process

Uncertainty Quantification Using Neural Networks for Molecular Property Prediction

Uncertainty quantification (UQ) is an important component of molecular property prediction, particularly for drug discovery applications where model predictions direct experimental design and where unanticipated imprecision wastes valuable time and resources. The need for UQ is especially acute for neural models, which are becoming increasingly standard yet are challenging to interpret. While several approaches to UQ have been proposed in the literature, there is no clear consensus on the comparative performance of these models. In this paper, we study this question in the context of regression tasks. We systematically evaluate several methods on five benchmark datasets using multiple complementary performance metrics. Our experiments show that none of the methods we tested is unequivocally superior to all others, and none produces a particularly reliable ranking of errors across multiple datasets. While we believe these results show that existing UQ methods are not sufficient for all common use-cases and demonstrate the benefits of further research, we conclude with a practical recommendation as to which existing techniques seem to perform well relative to others

NOVEL ALGORITHMS AND TOOLS FOR LIGAND-BASED DRUG DESIGN

Computer-aided drug design (CADD) has become an indispensible component in modern drug discovery projects. The prediction of physicochemical properties and pharmacological properties of candidate compounds effectively increases the probability for drug candidates to pass latter phases of clinic trials. Ligand-based virtual screening exhibits advantages over structure-based drug design, in terms of its wide applicability and high computational efficiency. The established chemical repositories and reported bioassays form a gigantic knowledgebase to derive quantitative structure-activity relationship (QSAR) and structure-property relationship (QSPR). In addition, the rapid advance of machine learning techniques suggests new solutions for data-mining huge compound databases. In this thesis, a novel ligand classification algorithm, Ligand Classifier of Adaptively Boosting Ensemble Decision Stumps (LiCABEDS), was reported for the prediction of diverse categorical pharmacological properties. LiCABEDS was successfully applied to model 5-HT1A ligand functionality, ligand selectivity of cannabinoid receptor subtypes, and blood-brain-barrier (BBB) passage. LiCABEDS was implemented and integrated with graphical user interface, data import/export, automated model training/ prediction, and project management. Besides, a non-linear ligand classifier was proposed, using a novel Topomer kernel function in support vector machine. With the emphasis on green high-performance computing, graphics processing units are alternative platforms for computationally expensive tasks. A novel GPU algorithm was designed and implemented in order to accelerate the calculation of chemical similarities with dense-format molecular fingerprints. Finally, a compound acquisition algorithm was reported to construct structurally diverse screening library in order to enhance hit rates in high-throughput screening